Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...
Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...
Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination Bayer to become first ...
The company published its latest quarterly earnings report this morning. It continues to draw limited revenue, while its costs are growing notably. For the quarter, Recursion -- which although a ...
Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest ...
AI-infused drug developer Recursion Pharmaceuticals has hired Najat Khan, Ph.D., as chief commercial officer and head of R&D. She joins from Johnson & Johnson where she was chief data science officer ...
The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...
RXRX's CDK7 inhibitor REC-617 has demonstrated activity but additional data from the ELUCIDATE trial in various solid tumors isn't expected until H2'25. Near-term catalysts include phase 2 TUPELO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback